Family Med Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

2. Omega-3 fatty acids for bipolar disorder

3. Is folic acid good for everyone

4. ACS Releases Guidelines for HPV Vaccination

5. Vitamin D - A review Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

The effects of adalimumab and methotrexate treatment on peripheral Th17 cells and IL-17/IL-6 secretion in rheumatoid arthritis patients
Rheumatology International, 10/28/09

AuthorLastNameFI et al. – Objective of the study is to assess the effects of adalimumab and MTX therapy on peripheral Th17 cells and IL-17/IL-6 secretion in RA patients. Adalimumab and MTX treatment down regulates peripheral Th17 cells and serum IL-6 level in RA patients. Baseline Th17 level negatively predicts the effect of adalimumb/MTX treatment

Methods

20 active RA patients were treated with oral MTX 15 mg per week , or hypodermal adalimumab 40 or 80 mg every other week
Peripheral blood samples taken for laboratory evaluation at week 0 and week 12 of treatment, including flowcytometric detection of peripheral CD4(+) IL-17(+) cells, RT-PCR detection of mRNA expressions of IL-17, RORc and FoxP3, and ELISA determination of serum IL-17 and IL-6
10 age and sex marched healthy volunteers included as normal controls
Results showed that (1) DAS28 in both groups improved at week 12 compared to week 0

Results

Results showed that (1) DAS28 in both groups improved at week 12 compared to week 0
2) The percentage and MFI of peripheral CD4(+) IL-17(+) cells in RA patients were significantly higher comparing to normal controls (1.64 ± 0.97% vs. 0.75 ± 0.20%, p < 0.01; and 29.8 ± 9.7 vs. 19.8 ± 4.6, and positively correlated with ESR and DAS28
Peripheral Th17 cells and serum IL-6 in RA patients decreased after treatment
Peripheral FoxP3 mRNA expression in active RA patients was significantly lower comparing to normal controls, and negatively correlated with ESR
Peripheral Th17 cells and serum IL-6 in RA patients decreased after treatment
Peripheral FoxP3 mRNA expression in active RA patients was significantly lower comparing to normal controls, and negatively correlated with ESR
Baseline Th17 percentage of RA patients negatively correlated with DAS28 improvement after treatment